NCT00449280View on ClinicalTrials.gov

Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

September 30, 2009

Conditions

Advanced Solid Tumor

Interventions

DRUG

Sorafenib

400mg BID (200 mg twice daily)

DRUG

Rapamycin

30mg once weekly

DRUG

Rapamycin

3mg once daily

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

University of Chicago

OTHER